Drug intelligence / Profile preview

PC-002L

Development stage: Preclinical
Lead developer: Cothera Bioscience
Modality: Small Molecules

Overview

PC-002L is a next-generation small molecule formulation of PC-002 (sepantronium bromide) being developed by Cothera Bioscience. It functions as an inhibitor of the deubiquitinase (DUB) enzyme USP7 (Ubiquitin-specific protease 7). By inhibiting USP7, the drug prevents the removal of ubiquitin chains from oncogenic proteins, thereby promoting their proteasomal degradation. This mechanism is particularly relevant in cancers driven by MYC family proteins, such as Small Cell Lung Cancer (SCLC) with N-MYC amplification, where the stabilization of these proteins is critical for tumor cell survival. PC-002L is designed to improve upon the pharmacological and therapeutic properties of the original PC-002 formulation and is currently in preclinical development.

Other names: next-generation formulation of PC-002

Targets

USP7

Beyond the preview

Go deeper on PC-002L.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PC-002L.

Explore the full profile